论文部分内容阅读
目的:探讨Bcl-2、Bax在不同类型子宫内膜腺上皮细胞中的表达。方法:采用免疫组化方法检测子宫内膜腺上皮细胞中Bcl-2、Bax的表达。结果:Bcl-2在正常增生期子宫内膜、子宫内膜增生症和子宫内膜腺癌的阳性表达率分别为100%、75%和57%,Bcl-2在子宫内膜癌的阳性表达率低于子宫内膜增生症和正常增生期子宫内膜,差异有统计学意义(P<0.05)。Bax在所有被检组织均呈阳性表达。从单纯性增生、复合性增生到不典型增生,Bcl-2的表达评分有逐渐下降的趋势,Bax的表达评分有逐渐增高的趋势,不典型增生与前二者相比差异均有统计学意义(P<0.05)。在内膜样腺癌中,随着分化程度的降低,分期的增加,Bcl-2和Bax表达评分下降。结论:Bcl-2、Bax参与子宫内膜癌的发生发展过程,且表达水平的不同有助于评估预后。
Objective: To investigate the expression of Bcl-2 and Bax in different types of endometrial glandular epithelial cells. Methods: Immunohistochemistry was used to detect the expression of Bcl-2 and Bax in endometrial glandular epithelial cells. Results: The positive rates of Bcl-2 expression in endometrial, endometrial hyperplasia and endometrial adenocarcinoma were 100%, 75% and 57%, respectively. The positive expression of Bcl-2 in endometrial carcinoma The rate was lower than that of endometrial hyperplasia and normal proliferative endometrium, the difference was statistically significant (P <0.05). Bax was positive in all the tested tissues. From simple hyperplasia, complex hyperplasia to atypical hyperplasia, Bcl-2 expression gradually decreased, Bax expression gradually increased, the difference between atypical hyperplasia and the former two were statistically significant (P <0.05). In endometrioid adenocarcinoma, the expression of Bcl-2 and Bax decreased with the decrease of differentiation and staging. Conclusion: Bcl-2 and Bax are involved in the development and progression of endometrial carcinoma, and the different expression levels of Bcl-2 and Bax may help to evaluate the prognosis.